Zurcher Kantonalbank Zurich Cantonalbank Acquires 7,382 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 8.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 91,955 shares of the medical research company's stock after purchasing an additional 7,382 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank owned approximately 0.05% of IQVIA worth $16,212,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in IQV. American National Bank & Trust acquired a new stake in IQVIA in the first quarter valued at approximately $26,000. Golden State Wealth Management LLC boosted its holdings in IQVIA by 295.5% in the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock worth $31,000 after buying an additional 130 shares during the period. AllSquare Wealth Management LLC purchased a new position in shares of IQVIA during the 1st quarter valued at $33,000. ST Germain D J Co. Inc. boosted its position in shares of IQVIA by 66.1% during the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after acquiring an additional 76 shares during the last quarter. Finally, GKV Capital Management Co. Inc. bought a new position in shares of IQVIA in the 4th quarter worth $39,000. Institutional investors and hedge funds own 89.62% of the company's stock.

Insider Buying and Selling

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of the business's stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the transaction, the insider owned 2,910 shares in the company, valued at $557,352.30. The trade was a 15.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Eric Sherbet sold 5,800 shares of the firm's stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the transaction, the insider directly owned 27,178 shares in the company, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is owned by insiders.

Analyst Ratings Changes

IQV has been the topic of several recent analyst reports. Barclays raised their target price on IQVIA from $165.00 to $185.00 and gave the stock an "equal weight" rating in a research note on Wednesday, July 23rd. Cowen reissued a "buy" rating on shares of IQVIA in a report on Wednesday, July 23rd. Evercore ISI raised their target price on shares of IQVIA from $170.00 to $180.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 9th. UBS Group boosted their price target on shares of IQVIA from $185.00 to $225.00 and gave the stock a "buy" rating in a research note on Wednesday, July 23rd. Finally, HSBC cut shares of IQVIA from a "buy" rating to a "hold" rating and decreased their target price for the company from $260.00 to $160.00 in a research report on Friday, April 25th. Seven equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $228.62.

IQVIA Stock Performance

Shares of IQV traded down $3.42 during mid-day trading on Friday, hitting $182.44. The stock had a trading volume of 1,644,130 shares, compared to its average volume of 2,321,248. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45. The company's fifty day simple moving average is $162.11 and its two-hundred day simple moving average is $170.07. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $252.88. The company has a market cap of $31.01 billion, a PE ratio of 26.40, a PEG ratio of 2.04 and a beta of 1.30.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating analysts' consensus estimates of $2.77 by $0.04. The business had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The business's revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter last year, the business earned $2.64 earnings per share. On average, equities analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.